46 related articles for article (PubMed ID: 29945498)
1. Expression analysis of Akirin-2, NFκB-p65 and β-catenin proteins in imatinib resistance of chronic myeloid leukemia.
Karabay AZ; Koc A; Ozkan T; Hekmatshoar Y; Altinok Gunes B; Sunguroglu A; Buyukbingol Z; Atalay A; Aktan F
Hematology; 2018 Dec; 23(10):765-770. PubMed ID: 29945498
[TBL] [Abstract][Full Text] [Related]
2. A conserved ZFX/WNT3 axis modulates the growth and imatinib response of chronic myeloid leukemia stem/progenitor cells.
Zhang X; Wang Y; Lu J; Xiao L; Chen H; Li Q; Li YY; Xu P; Ruan C; Zhou H; Zhao Y
Cell Mol Biol Lett; 2023 Oct; 28(1):83. PubMed ID: 37864206
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate affects extracellular ATP catabolism and expression of NTPDases in a chronic myeloid leukemia cell line.
Willig JB; Vianna DRB; Beckenkamp A; Beckenkamp LR; Sévigny J; Wink MR; Buffon A; Pilger DA
Purinergic Signal; 2020 Mar; 16(1):29-40. PubMed ID: 31955347
[TBL] [Abstract][Full Text] [Related]
4. Targeting mitochondrial bioenergetics by combination treatment with imatinib and dichloroacetate in human erythroleukemic K‑562 and colorectal HCT‑116 cancer cells.
Kakafika MG; Lyta AA; Gavriilidis GI; Tsiftsoglou SA; Miliotou AN; Pappas IS; Vizirianakis IS; Papadopoulou LC; Tsiftsoglou AS
Int J Oncol; 2024 Apr; 64(4):. PubMed ID: 38426621
[TBL] [Abstract][Full Text] [Related]
5. Hyaluronan-mediated CD44 interaction with p300 and SIRT1 regulates beta-catenin signaling and NFkappaB-specific transcription activity leading to MDR1 and Bcl-xL gene expression and chemoresistance in breast tumor cells.
Bourguignon LYW; Xia W; Wong G
J Biol Chem; 2009 Jan; 284(5):2657-2671. PubMed ID: 19047049
[TBL] [Abstract][Full Text] [Related]
6. Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia.
He X; Deng Y; Yue W
Mol Med Rep; 2017 Jul; 16(1):523-532. PubMed ID: 28560425
[TBL] [Abstract][Full Text] [Related]
7. A Deeply Quiescent Subset of CML LSC depend on FAO yet Avoid Deleterious ROS by Suppressing Mitochondrial Complex I.
Chimge NO; Chen MH; Nguyen C; Zhao Y; Wu X; Gonzalez PG; Ogana H; Hurwitz S; Teo JL; Chen X; Du J; Jin V; Kim YM; Ono M; Argüello RJ; Kahn M
Curr Mol Pharmacol; 2024; 17(1):e060923220758. PubMed ID: 37691195
[TBL] [Abstract][Full Text] [Related]
8. The gamma catenin/CBP complex maintains survivin transcription in β-catenin deficient/depleted cancer cells.
Kim YM; Ma H; Oehler VG; Gang EJ; Nguyen C; Masiello D; Liu H; Zhao Y; Radich J; Kahn M
Curr Cancer Drug Targets; 2011 Feb; 11(2):213-25. PubMed ID: 21158719
[TBL] [Abstract][Full Text] [Related]
9. AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects.
Gayatri MB; Kancha RK; Behera A; Patchva D; Velugonda N; Gundeti S; Reddy ABM
Cell Death Discov; 2023 Oct; 9(1):401. PubMed ID: 37903788
[TBL] [Abstract][Full Text] [Related]
10. The BCR-ABL1 Inhibitors Imatinib and Ponatinib Decrease Plasma Cholesterol and Atherosclerosis, and Nilotinib and Ponatinib Activate Coagulation in a Translational Mouse Model.
Pouwer MG; Pieterman EJ; Verschuren L; Caspers MPM; Kluft C; Garcia RA; Aman J; Jukema JW; Princen HMG
Front Cardiovasc Med; 2018; 5():55. PubMed ID: 29946549
[TBL] [Abstract][Full Text] [Related]
11. Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?
Osorio S; Escudero-Vilaplana V; Gómez-Centurión I; Pérez-López R; Ayala R; Vall-Llovera F; García-Gutierrez V; Gómez Casares MT; González San Miguel JD; Hernández-Rivas JÁ; Sánchez-Guijo F; Martínez-García AB; Villalón L; Conesa-García V; Rodriguez A; Casado F; Garcia-Gonzalez X; Sáez Perdomo MN; Baños Ú; Steegmann JL;
Ann Hematol; 2018 Nov; 97(11):2089-2098. PubMed ID: 29955943
[TBL] [Abstract][Full Text] [Related]
12. Features of vascular adverse events in Japanese patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a retrospective study of the CML Cooperative Study Group database.
Fujioka I; Takaku T; Iriyama N; Tokuhira M; Kimura Y; Sato E; Ishikawa M; Nakazato T; Sugimoto KJ; Fujita H; Asou N; Kizaki M; Hatta Y; Komatsu N; Kawaguchi T
Ann Hematol; 2018 Nov; 97(11):2081-2088. PubMed ID: 29946911
[TBL] [Abstract][Full Text] [Related]
13. Genetic Polymorphism on the Pharmacokinetics and Pharmacodynamics of Platelet-derived Growth Factor Receptor (PDGFR) Kinase Inhibitors.
Qian Y; Yu L; Zhang XH; Yuan ZQ; Zhao P; Sun LN; Wang YQ
Curr Drug Metab; 2018; 19(14):1168-1181. PubMed ID: 29956623
[TBL] [Abstract][Full Text] [Related]
14. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms.
Boddu P; Chihara D; Masarova L; Pemmaraju N; Patel KP; Verstovsek S
Ann Hematol; 2018 Nov; 97(11):2071-2080. PubMed ID: 29951914
[TBL] [Abstract][Full Text] [Related]
15. Association between Altered Expression and Genetic Variations of Transforming Growth Factor β-Smad Pathway with Chronic Myeloid Leukemia.
Shokeen Y; Sharma NR; Vats A; Dinand V; Beg MA; Sanskaran S; Minhas S; Jauhri M; Hariharan AK; Taneja V; Aggarwal S
Int J Hematol Oncol Stem Cell Res; 2018 Jan; 12(1):14-22. PubMed ID: 29951173
[No Abstract] [Full Text] [Related]
16. Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.
De Roeck L; Michaux L; Debackere K; Lierman E; Vandenberghe P; Devos T
Hematology; 2018 Dec; 23(10):785-792. PubMed ID: 29993347
[TBL] [Abstract][Full Text] [Related]
17. Deep sequencing of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia patients with resistance to tyrosine kinase inhibitors.
Erbilgin Y; Eskazan AE; Hatirnaz Ng O; Salihoglu A; Elverdi T; Firtina S; Tasar O; Mercan S; Sisko S; Khodzhaev K; Ongoren S; Ar MC; Baslar Z; Soysal T; Sayitoglu M; Ozbek U
Leuk Lymphoma; 2019 Jan; 60(1):200-207. PubMed ID: 29965782
[TBL] [Abstract][Full Text] [Related]
18. The evaluation of the anti-cancer effects of Anoectochilus roxburghii on hematological cancers in vitro.
Gunes BA; Ozkan T; Gonulkirmaz N; Sunguroglu A
Med Oncol; 2023 Dec; 41(1):6. PubMed ID: 38044345
[TBL] [Abstract][Full Text] [Related]
19. Systematic Analysis of Molecular Subtypes and Immune Prediction Based on CD8 T Cell Pattern Genes Based on Head and Neck Cancer.
Yanwei L; He F; Liu S; Pan Z
J Oncol; 2022; 2022():1500493. PubMed ID: 36059811
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Mojtahedi H; Yazdanpanah N; Rezaei N
Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
